This Human IGFLR1 (TMEM149, U2AF1L4) recombinant protein was produced in Mammalian cell, where the gene sequence encoding Human IGFLR1 (23-163aa) was expressed with the C-terminal 6xHis tag. The purity of this IGFLR1 protein was greater than 95% by SDS-PAGE. The activity was measured by its binding ability in a functional ELISA.
IGFLR1 may also be involved in the immune system as a member of the TNF receptor family. Studies have found that in colorectal cancer, IGFLR1 is highly expressed on the surface of CD8+ T cells and has the function of depleting T cells. Inhibiting the expression of IGFLR1 may slow the progression of colorectal cancer tumors. In colorectal cancer patients, CXCL13+TH1-like cells may affect the therapeutic effect of immune checkpoint inhibitors. IGFLR1 is a type of receptor protein that is highly expressed on CXCL13+TH1-like cells. In vitro experiments in vivo demonstrated that IGFLR1, as a co-stimulatory factor, may become a potential drug therapy target. Email: support@cusabio.com
Distributors Worldwide